

THE LANCET

Gastroenterology & Hepatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Adams R, Brown E, Brown L, et al, on behalf of the FOCUS4 Trial Investigators. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for *BRAF*, *PIK3CA*, *KRAS*, and *NRAS* (FOCUS4-D): a phase 2–3 randomised trial. *Lancet Gastroenterol Hepatol* 2017; published online Dec 15. [http://dx.doi.org/10.1016/S2468-1253\(17\)30394-1](http://dx.doi.org/10.1016/S2468-1253(17)30394-1).

Table: Toxicities by randomised group, according to NCI CTC version 3.0

| | Placebo | | AZD8931 | |
|----------------------------|------------------|------------------|-------------------|-------------------|
| | G1/2 | G3 | G1/2 | G3 |
| Nausea | 4 (25%) | 0 (0%) | 4 (27%) | 0 (0%) |
| Vomiting | 1 (6%) | 0 (0%) | 4 (27%) | 0 (0%) |
| Diarrhoea | 4 (25%) | 1 (6%) | 11 (73%) | 1 (7%) |
| Stomatitis | 0 (0%) | 0 (0%) | 4 (27%) | 0 (0%) |
| Dry skin | 2 (13%) | 0 (0%) | 9 (60%) | 0 (0%) |
| Skin rash | 3 (19%) | 0 (0%) | 11 (73%) | 3 (20%) |
| Acne | 4 (25%) | 0 (0%) | 7 (47%) | 0 (0%) |
| PPE | 2 (13%) | 0 (0%) | 4 (27%) | 0 (0%) |
| Anaemia | 6 (38%) | 0 (0%) | 6 (40%) | 1 (7%) |
| Neutropenia | 2 (13%) | 0 (0%) | 2 (13%) | 0 (0%) |
| Thrombocytopenia | 3 (19%) | 0 (0%) | 1 (7%) | 0 (0%) |
| Hyperbilirubinaemia | 1 (6%) | 0 (0%) | 3 (20%) | 1 (7%) |
| Transaminitis | 0 (0%) | 0 (0%) | 4 (27%) | 0 (0%) |
| Hypomagnesaemia | 1 (6%) | 0 (0%) | 2 (13%) | 0 (0%) |
| Cardiac toxicity | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Pneumonitis | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) |
| Infection | 2 (13%) | 0 (0%) | 3 (20%) | 1 (7%) |
| Dry eyes | 1 (6%) | 0 (0%) | 2 (13%) | 1 (7%) |
| Photophobia | 1 (6%) | 0 (0%) | 1 (7%) | 0 (0%) |
| Blurred vision | 0 (0%) | 0 (0%) | 4 (27%) | 0 (0%) |
| Conjunctivitis | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) |
| Corneal ulcer | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Fatigue | 7 (44%) | 0 (0%) | 12 (80%) | 0 (0%) |
| Paronychia | 0 (0%) | 0 (0%) | 3 (20%) | 0 (0%) |
| Epistaxis | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) |
| Cystitis | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) |
| Total | 16 (100%) | 16 (100%) | 15* (100%) | 15* (100%) |

* missing data for one patient in AZD8931 arm

N.B. No toxicities of CTC grade 4 or 5 were reported.